These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 25495406)

  • 1. Polymorphic expression of CYP2C19 and CYP2D6 in the developing and adult human brain causing variability in cognition, risk for depression and suicide: the search for the endogenous substrates.
    Ingelman-Sundberg M; Persson A; Jukic MM
    Pharmacogenomics; 2014; 15(15):1841-4. PubMed ID: 25495406
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical validity: Combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes.
    Altar CA; Carhart JM; Allen JD; Hall-Flavin DK; Dechairo BM; Winner JG
    Pharmacogenomics J; 2015 Oct; 15(5):443-51. PubMed ID: 25686762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of antidepressants with pharmacogenetic prescribing guidelines in a 10-year depression cohort of adult primary care patients.
    Jessel CD; Mostafa S; Potiriadis M; Everall IP; Gunn JM; Bousman CA
    Pharmacogenet Genomics; 2020 Sep; 30(7):145-152. PubMed ID: 32433340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Completed suicides of citalopram users-the role of CYP genotypes and adverse drug interactions.
    Rahikainen AL; Vauhkonen P; Pett H; Palo JU; Haukka J; Ojanperä I; Niemi M; Sajantila A
    Int J Legal Med; 2019 Mar; 133(2):353-363. PubMed ID: 30173302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High frequency of occurrence of CYP2D6 gene duplication/multiduplication indicating ultrarapid metabolism among suicide cases.
    Zackrisson AL; Lindblom B; Ahlner J
    Clin Pharmacol Ther; 2010 Sep; 88(3):354-9. PubMed ID: 19907421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder.
    Brandl EJ; Tiwari AK; Zhou X; Deluce J; Kennedy JL; Müller DJ; Richter MA
    Pharmacogenomics J; 2014 Apr; 14(2):176-81. PubMed ID: 23545896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A combined high CYP2D6-CYP2C19 metabolic capacity is associated with the severity of suicide attempt as measured by objective circumstances.
    Peñas-Lledó E; Guillaume S; Naranjo ME; Delgado A; Jaussent I; Blasco-Fontecilla H; Courtet P; LLerena A
    Pharmacogenomics J; 2015 Apr; 15(2):172-6. PubMed ID: 25113522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complications of Psychotropic and Pain Medications in an Ultrarapid Metabolizer Patient at the Upper 1% of Cytochrome P450 (CYP450) Function Quantified by Combinatorial CYP450 Genotyping.
    Ruaño G; Larsen K; Kocherla M; Graydon JS; Kost J
    J Pain Palliat Care Pharmacother; 2017 Jun; 31(2):126-138. PubMed ID: 28506184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population.
    Scott SA; Edelmann L; Kornreich R; Erazo M; Desnick RJ
    Pharmacogenomics; 2007 Jul; 8(7):721-30. PubMed ID: 18240905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A one-year follow-up study of treatment-compliant suicide attempt survivors: relationship of CYP2D6-CYP2C19 and polypharmacy with suicide reattempts.
    Peñas-Lledó EM; Guillaume S; de Andrés F; Cortés-Martínez A; Dubois J; Kahn JP; Leboyer M; Olié E; LLerena A; Courtet P
    Transl Psychiatry; 2022 Oct; 12(1):451. PubMed ID: 36257936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.
    Scordo MG; Caputi AP; D'Arrigo C; Fava G; Spina E
    Pharmacol Res; 2004 Aug; 50(2):195-200. PubMed ID: 15177309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of pharmacogenomic testing in psychiatry: Real world examples.
    Dinama O; Warren AM; Kulkarni J
    Aust N Z J Psychiatry; 2014 Aug; 48(8):778. PubMed ID: 24413808
    [No Abstract]   [Full Text] [Related]  

  • 13. CYP2D6 and CYP2C19 genotypes and amitriptyline metabolite ratios in a series of medicolegal autopsies.
    Koski A; Sistonen J; Ojanperä I; Gergov M; Vuori E; Sajantila A
    Forensic Sci Int; 2006 May; 158(2-3):177-83. PubMed ID: 16024198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention Trial.
    Serrano D; Lazzeroni M; Zambon CF; Macis D; Maisonneuve P; Johansson H; Guerrieri-Gonzaga A; Plebani M; Basso D; Gjerde J; Mellgren G; Rotmensz N; Decensi A; Bonanni B
    Pharmacogenomics J; 2011 Apr; 11(2):100-7. PubMed ID: 20309015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-response to consecutive antidepressant therapy caused by CYP2D6 ultrarapid metabolizer phenotype.
    Breil F; Verstuyft C; Orostegui L; Buhl C; Alvarez JC; Chouinard G; Becquemont L; Corruble E
    Int J Neuropsychopharmacol; 2008 Aug; 11(5):727-8. PubMed ID: 18384706
    [No Abstract]   [Full Text] [Related]  

  • 16. How common are drug and gene interactions? Prevalence in a sample of 1143 patients with CYP2C9, CYP2C19 and CYP2D6 genotyping.
    Verbeurgt P; Mamiya T; Oesterheld J
    Pharmacogenomics; 2014 Apr; 15(5):655-65. PubMed ID: 24798722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personalised prescribing in psychiatry: Has pharmacogenomics delivered on its promise?
    Foulds JA; Maggo SD; Kennedy MA
    Aust N Z J Psychiatry; 2016 Jun; 50(6):509-10. PubMed ID: 27012968
    [No Abstract]   [Full Text] [Related]  

  • 18. Towards the implementation of CYP2D6 and CYP2C19 genotypes in clinical practice: update and report from a pharmacogenetic service clinic.
    Müller DJ; Kekin I; Kao AC; Brandl EJ
    Int Rev Psychiatry; 2013 Oct; 25(5):554-71. PubMed ID: 24151801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The crucial role of the therapeutic window in understanding the clinical relevance of the poor versus the ultrarapid metabolizer phenotypes in subjects taking drugs metabolized by CYP2D6 or CYP2C19.
    de Leon J
    J Clin Psychopharmacol; 2007 Jun; 27(3):241-5. PubMed ID: 17502769
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacogenetic testing among patients with depression in a US managed care population.
    Anderson HD; Thant TM; Kao DP; Crooks KR; Mendola ND; Aquilante CL
    Clin Transl Sci; 2022 Jul; 15(7):1644-1653. PubMed ID: 35385214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.